Patient scheduling for gonadotrophin-releasing hormone antagonist protocols

References

• Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Human Reproduction 2001; 16: 868–870
   PubMed Web of Science ®Google Scholar
• Anderson RE, Stein AL, Paulson RJ, Stanczyk FZ, Vijod AG, Lobo RA. Effects of norethindrone on gonadotropin and ovarian steroid secretion when used for cycle programming during in vitro fertilization. Fertility and Sterility 1990; 54: 96–101
   PubMed Web of Science ®Google Scholar
• Aston K, Arthur I, Masson GM, Jenkins JM. Progestogen therapy and prevention of functional ovarian cysts during pituitary desensitisation with GnRH agonists. British Journal of Obstetrics and Gynaecology 1995; 102: 835–837
   Google Scholar
• Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertility and Sterility 1998a; 70: 1063–1069
   PubMedGoogle Scholar
• Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues. Journal of Assisted Reproduction and Genetics 1998b; 15: 599–604
   PubMedGoogle Scholar
• Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction 2000; 15: 1490–1498
   PubMed Web of Science ®Google Scholar
• Branigan EF, Estes MA. Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression. Fertility and Sterility 2000; 73: 587–590
   PubMed Web of Science ®Google Scholar
• Clifford K, Rai R, Watson H, Franks S, Regan L. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. British Medical Journal 1996; 312: 1508–1511
   PubMed Web of Science ®Google Scholar
• Cramer DW, Powers DR, Oskowitz SP, Liberman RF, Hornstein MD, McShane PM, Barbieri RL. Gonadotropin-releasing hormone agonist use in assisted reproduction cycles: the influence of long and short regimens on pregnancy rates. Fertility and Sterility 1999; 72: 83–89
   PubMedGoogle Scholar
• Daya S. Optimal protocol for gonadotropin-releasing hormone agonist use in ovarian stimulation. In Vitro Fertilization and Assisted Reproduction, V Gomel, PCK Cheung. Monduzzi Editore, Bologna 1997; 405–415, In
   Google Scholar
• de Jong D, Macklon NS, Fauser BC. A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the ‘follicle-stimulating hormone window˚s combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertility and Sterility 2000; 73: 1051–1054
   PubMed Web of Science ®Google Scholar
• de Jong D, Macklon NS, Eijkemans MJ, Mannaerts BM, Coelingh Bennink HJ, Fauser BC. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). Fertility and Sterility 2001; 75: 688–693
   PubMed Web of Science ®Google Scholar
• Fakuda M, Fakuda K, Yding Anderson C, Byskov AG. Does anovulation induced by oral contraceptives favor pregnancy during the following two menstrual cycles?. Fertility and Sterility 2000; 73: 742–747
   Google Scholar
• Fauser BC, Devroey P, Yen SS, Gosden R, Crowley WF, Jr, Baird DT, Bouchard P. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Human Reproduction 1999; 14: 2681–2686
   PubMed Web of Science ®Google Scholar
• Feldberg D, Farhi J, Ashkenzi J, Dicker D, Shalev J, Ben Rafael Z. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertility and Sterility 1992; 62: 343–346
   Google Scholar
• Fischl, F, Aboulghar, Mar`es, et al. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 2001; 16: 644–651
   Google Scholar
• Fleming R, Coutts JR. Induction of multiple follicular growth in normally menstruating women with endogenous gonadotropin suppression. Fertility and Sterility 1986; 45: 226–230
   PubMed Web of Science ®Google Scholar
• Fluker, M, Grifo, J, Leader, A, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 2001; 75: 38–45
   PubMed Web of Science ®Google Scholar
• Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertility and Sterility 1992; 58: 888–896
   PubMed Web of Science ®Google Scholar
• Jansen CAM, Tucker KE. Gonadotrophins-only based controlled ovarian hyperstimulation protocols: benefits and drawbacks. Textbook of Assisted Reproductive Techniques. Laboratory and Clinical Perspectives, DK Gardener, A Weissman, CM Howles, Z Shoham. Martin Dunitz, London 2001; 473–481, In
   Google Scholar
• Jansen CAM, van Os HC, Out HJ, Coelingh Bennink HJT. A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotropins (Humegon) in non-downregulated in vitro fertilisation patients. Human Reproduction 1988; 13: 2995–2999
   Google Scholar
• Lockwood GM, Muttukrishna S, Ledger WL, Groome NP, Dolfing J, Jansen CAM. Optimisation of non-analogue IVF: a role for inhibin b in predicting patients liable to premature LH surge or inadequate response. Human Reproduction 1997; 12S: 157–158
   Google Scholar
• Mashiach, S, Dor, J, Goldenberg, M, et al. Programmed oocyte retrieval: clinical and biological effects of oral contraceptives administered before in vitro fertilization. Gynecological Endocrinology 1989; 3: 107–115
   PubMed Web of Science ®Google Scholar
• Oussaid B, Lonergan P, Khatir H, Guler A, Monniaux D, Touze JL, Beckers JF, Cognie Y, Mermillod P. Effect of GnRH antagonist-induced prolonged follicular phase on follicular atresia and oocyte developmental competence in vitro in superovulated heifers. Journal of Reproduction and Fertility 2000; 118: 137–144
   Google Scholar
• Pados G, Tarlatzis BC, Bontis J, Lagos S, Papadimas J, Spanos E, Mantalenakis S. Evaluation of different ovarian stimulation protocols for in vitro fertilization. Gynecological Endocrinology 1995; 9: 103–112
   Web of Science ®Google Scholar
• Silva CC, Knight PG. Effects of androgens, progesterone and their antagonists on the developmental competence of in vitro matured bovine oocytes. Journal of Reproduction and Fertility 2000; 119: 261–269
   Google Scholar
• Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertility and Sterility 1998; 69: 419–424
   PubMed Web of Science ®Google Scholar
• van Loenen ACD, Huirne JAF, Schats R, Donnez J, Lambalk CB. An open-label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH-antagonist in patients undergoing ART (IVF-ICSI) treatment. 17th Annual Meeting of the ESHRE, LausanneSwitzerland, 2001, Abstract P-109
   Google Scholar